A prodrug form of temocaprilat
Related Products
Active Metabolite(s)
22169Temocaprilat
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Temocapril (hydrochloride)

Item No. 18241

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
6-[[(1S)-1-(ethoxycarbonyl)3-phenylpropyl]amino]tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5H)-acetic acid, monohydrochloride
CAS Number
110221-44-8
Synonyms
  • CS 622
Molecular Formula
C23H28N2O5S2 • HCl
Formula Weight
513.1
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mLDMF:PBS(pH 7.2)(1:1): 0.5 mg/mLDMSO: 20 mg/mLEthanol: 1 mg/mL
λmax
233 nm
SMILES
OC(CN1C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(OCC)=O)CS[C@H](C3=CC=CS3)C1)=O)=O.Cl
InChi Code
InChI=1S/C23H28N2O5S2.ClH/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27;/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27);1H/t17-,18-,20-;/m0./s1
InChi Key
XDDQNOKKZKHBIX-ASBZXGSUSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $36

    Add

    10 mg

    $68

    Add

    25 mg

    $128

    Add

    50 mg

    $236

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Temocapril is a prodrug form of the angiotensin-converting enzyme (ACE) inhibitor temocaprilat (Item No. 22169).1 Temocapril is converted to temocaprilat by carboxylesterase 1 (CES1).2 It prevents impairment of acetylcholine-induced relaxation in aortic rings isolated from diabetic rats in a model of streptozotocin-induced diabetes.3 Temocapril (0.1, 0.3, and 1 mg/kg) inhibits the angiotensin I-induced pressor response in normotensive rats.1 It prevents coronary vascular remodeling induced by L-NAME (Item No. 80210) in rats when administered at 0.1 mg/ml in the drinking water.4 Temocapril (1 mg/kg) reduces plasma glucose levels in a KKAy mouse model of type 2 diabetes.5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Oizumi, K., Koike, H., Sada, T., et al. Pharmacological profiles of CS-622, a novel angiotensin converting enzyme inhibitor. Jpn. J. Pharmacol. 48(3), 349-356 (1988).

    2. Furihata, T., Hosokawa, M., Koyano, N., et al. Identification of di-(2-ethylhexyl) phthalate-induced carboxylesterase 1 in C57BL/6 mouse liver microsomes: Purification, cDNA cloning, and baculovirus-mediated expression. Drug Metab. Dispos. 32(10), 1170-1177 (2004).

    3. Pieper, G.M., and Siebeneich, W. Temocapril, an angiotensin converting enzyme inhibitor, protects against diabetes-induced endothelial dysfunction. Eur. J. Pharmacol. 403(1-2), 129-132 (2000).

    4. Takemoto, M., Egashira, K., Tomita, H., et al. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 30(6), 1621-1627 (1997).

    5. Shiuchi, T., Cui, T.-X., Wu, L., et al. ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 40(3), 329-334 (2002).